News and Announcements
Proteomics PromarkerD Test Kit Production Deal Signed
- Published November 16, 2016 9:41AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
11th November 2016, ASX Announcement
Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) today reached a strategic milestone in its commercialisation pathway for PromarkerD, the company’s predictive test for diabetic kidney disease.
- PILL signs production contract with Monash Antibody Technologies Facility
- Custom antibodies will be designed to recognise the diabetic kidney disease ‘fingerprints’
- Strategic milestone in production of a pathology lab test
The company has signed a contract with the Monash Antibody Technologies Facility to produce the custom antibodies needed for a multiplex ELISA (Enzyme-linked immunosorbent assay), which is the precursor to a pathology lab In vitro Diagnostic (IVD) test.
To view the full announcement, please click on the button below.